AACR 2024 | PSMA PET findings in 225AC-J591-treated patients with mCRPC

Andres Ricaurte-Fajardo, MD, Weill Cornell Medicine, New York, NY, gives an overview of results from a study assessing actinium-225-PSMA-J591 (225AC-J591) in patients with metastatic castration-resistant prostate cancer (mCRPC). PSMA PET imaging responses were positive in patients who received 225AC-J591, where it was associated with progression-free survival (PFS). Assessment of total tumor volume is additionally underway to further elucidate its potential link with PFS. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.